Business

Novocure to Report First Quarter 2022 Financial Results

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday,

articleNovocure LimitedApril 1, 20223/company/novocure-ltd/news/novocure-to-report-first-quarter-2022-financial-results-2022-04-01
Novocure to Report First Quarter 2022 Financial Results

About this update from Novocure Limited

[{"type":"text","content":" ST. HELIER, Jersey--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three months ended March 31, 2022, at 8 a.m. EDT on Thursday, April 28, 2022. Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 1476184.\n\nThe webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.\n\nAbout Novocure\n\nNovocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.\n\nHeadquartered in Jersey, and with a growing global footprint, Novocure has regional operating centers in Root, Switzerland, Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.\n\nForward-Looking Statements\n\nIn addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific prog...

More updates from Novocure Limited